MA32687B1 - Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale - Google Patents

Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale

Info

Publication number
MA32687B1
MA32687B1 MA33736A MA33736A MA32687B1 MA 32687 B1 MA32687 B1 MA 32687B1 MA 33736 A MA33736 A MA 33736A MA 33736 A MA33736 A MA 33736A MA 32687 B1 MA32687 B1 MA 32687B1
Authority
MA
Morocco
Prior art keywords
modified release
skin
application
vaginal mucosa
emulsions
Prior art date
Application number
MA33736A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Emanuela Mura
Federico Mailland
Daniela Ceriani
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40340663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32687(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MA32687B1 publication Critical patent/MA32687B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
MA33736A 2008-10-08 2011-04-01 Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale MA32687B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08166058A EP2174650A1 (en) 2008-10-08 2008-10-08 Modified release emulsions for application to skin or vaginal mucosa
PCT/EP2009/062190 WO2010040632A1 (en) 2008-10-08 2009-09-21 Modified release emulsions for application to skin or vaginal mucosa

Publications (1)

Publication Number Publication Date
MA32687B1 true MA32687B1 (fr) 2011-10-02

Family

ID=40340663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33736A MA32687B1 (fr) 2008-10-08 2011-04-01 Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale

Country Status (19)

Country Link
US (1) US20110195944A1 (https=)
EP (2) EP2174650A1 (https=)
JP (1) JP2012505171A (https=)
KR (1) KR20110067115A (https=)
CN (1) CN102170862A (https=)
AR (1) AR073801A1 (https=)
AU (1) AU2009301275A1 (https=)
BR (1) BRPI0920565A2 (https=)
CA (1) CA2737255A1 (https=)
CL (1) CL2011000767A1 (https=)
CO (1) CO6361898A2 (https=)
EA (1) EA201170555A1 (https=)
IL (1) IL211681A0 (https=)
MA (1) MA32687B1 (https=)
MX (1) MX2011003696A (https=)
NZ (1) NZ591919A (https=)
PE (1) PE20110449A1 (https=)
WO (1) WO2010040632A1 (https=)
ZA (1) ZA201101818B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286056B2 (en) * 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
US9056137B2 (en) 2011-04-01 2015-06-16 University Of Florida Research Foundation, Incorporated Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
DE102011076869A1 (de) * 2011-06-01 2012-12-06 Beiersdorf Ag Emulsionszubereitungen mit verbesserten rheologischen Eigenschaften
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN110075310A (zh) 2011-12-20 2019-08-02 维奥姆治疗有限公司 用于治疗真菌感染的局部油组合物
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014167554A2 (en) * 2013-04-12 2014-10-16 Vyome Biosciences Pvt. Ltd. Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
CA2942345C (en) * 2014-03-12 2020-12-01 Warner Chilcott Company, Llc Low-dose estradiol cream
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3040422A1 (en) * 2016-10-13 2018-04-19 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
KR20200019735A (ko) * 2017-06-22 2020-02-24 비라말 리미티드 약물 전달을 위한 조성물 및 그의 사용 방법
WO2019213473A1 (en) 2018-05-04 2019-11-07 The Procter & Gamble Company Compositions and methods for treating vaginal dryness
BR112021007877A2 (pt) 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414511T1 (de) * 2000-12-05 2008-12-15 Los Angeles Childrens Hospital Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung
US20030228340A1 (en) * 2002-04-04 2003-12-11 Gans Eugene H. Methods for treating rosacea with pyridones
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20060233721A1 (en) * 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
CA2611577A1 (en) * 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US20070071705A1 (en) * 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
US20080075745A1 (en) * 2006-09-21 2008-03-27 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions containing ciclopirox or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
EP2331065A1 (en) 2011-06-15
PE20110449A1 (es) 2011-07-07
JP2012505171A (ja) 2012-03-01
AR073801A1 (es) 2010-12-01
MX2011003696A (es) 2011-06-20
US20110195944A1 (en) 2011-08-11
CA2737255A1 (en) 2010-04-15
AU2009301275A2 (en) 2011-04-28
CN102170862A (zh) 2011-08-31
NZ591919A (en) 2012-09-28
CL2011000767A1 (es) 2011-06-17
ZA201101818B (en) 2012-05-30
WO2010040632A1 (en) 2010-04-15
BRPI0920565A2 (pt) 2015-12-29
IL211681A0 (en) 2011-06-30
KR20110067115A (ko) 2011-06-21
EA201170555A1 (ru) 2011-12-30
AU2009301275A1 (en) 2010-04-15
EP2174650A1 (en) 2010-04-14
CO6361898A2 (es) 2012-01-20

Similar Documents

Publication Publication Date Title
MA32687B1 (fr) Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale
Li et al. In vitro transdermal delivery of therapeutic antibodies using maltose microneedles
RU2469726C2 (ru) Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
FR2930140B1 (fr) Dispositif pour la conservation, la preparation extemporanee et l'administration d'un faible dosage de principe actif
Brandt et al. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy
WO2007117352A3 (en) Topical therapeutic delivery system
AR044050A1 (es) Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos
UY30373A1 (es) Derivados de fenilalanina, procedimientos de preparacion y aplicaciones
Wu et al. Tetramethylpyrazine nitrone reduces oxidative stress to alleviate cerebral vasospasm in experimental subarachnoid hemorrhage models
KR20180023965A (ko) 디아세레인 또는 레인 국소 제형 및 이의 용도
ES2975363T3 (es) Tratamiento de lesión traumática aguda
RU2424804C2 (ru) Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость
WO2008058220A2 (en) Transdermal drug delivery system
Sant et al. Influence of oleic acid on the rheology and in vitro release of lumiracoxib from poloxamer gels
BRPI0403269A (pt) emulsão múltipla
WO2017006112A1 (en) Composition and methods of treatment
Kelmann et al. Pentyl gallate nanoemulsions as potential topical treatment of herpes labialis
Li et al. Development of patch and spray formulations for enhancing topical delivery of sinomenine hydrochloride
US20200206160A1 (en) Composition and methods of treatment
US20130023572A1 (en) Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
ES2498521B1 (es) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
Li et al. Synergistic effect of 1, 4-cyclohexanediol and 1, 2-hexanediol on percutaneous absorption and penetration of metronidazole
HK1153674A (en) Modified release emulsions for application to skin or vaginal mucosa
WO2006113227A3 (en) Compositions facilitating drug penetration and drug retention in skin
US12194026B2 (en) Drug for treating tinnitus